Endpoints News
@endpts.com
We're where the business of medicine gets answers. An independent news media organization covering biotech, pharma, science, policy, finance, venture capital and markets, and how they drive the life sciences industry. Read us at www.endpts.com.
Pinned
Endpoints News
@endpts.com
· Dec 17
Just finding us here? Endpoints News has a starter pack with our journalists so you can follow the team!
go.bsky.app/NzDRUhL
go.bsky.app/NzDRUhL
Neurocrine said one of the drugs it licensed from Takeda failed a Phase 2 trial in major depressive disorder.
endpoints.news/neurocrine-r...
endpoints.news/neurocrine-r...
Neurocrine reports Phase 2 fail for depression drug it licensed from Takeda
Neurocrine Biosciences said that a candidate for major depressive disorder that it got from Takeda did not succeed in a mid-stage trial.
endpoints.news
November 11, 2025 at 3:55 PM
Neurocrine said one of the drugs it licensed from Takeda failed a Phase 2 trial in major depressive disorder.
endpoints.news/neurocrine-r...
endpoints.news/neurocrine-r...
The FDA plans to pull boxed warnings from the labels of menopause hormone therapies. It's working with companies to remove “references to risks of breast cancer, cardiovascular disease, and probable dementia.”
FDA seeks to remove warnings from labels of hormone therapies for menopause
The FDA is making a concerted effort to increase access to hormone replacement therapies (HRTs) for women by calling on their makers to apply to remove the boxed warnings that the agency added to thei...
endpoints.news
November 10, 2025 at 9:42 PM
The FDA plans to pull boxed warnings from the labels of menopause hormone therapies. It's working with companies to remove “references to risks of breast cancer, cardiovascular disease, and probable dementia.”
Former Lilly Diabetes executives Enrique Conterno and Meg Powell are searching for the newest approaches to obesity treatment with their venture capital firm, 501 Ventures.
Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm aimed at 'advancing the science'
Two former executives of Eli Lilly's diabetes unit are searching for the newest and best approaches to obesity treatment.
endpoints.news
November 10, 2025 at 7:00 PM
Former Lilly Diabetes executives Enrique Conterno and Meg Powell are searching for the newest approaches to obesity treatment with their venture capital firm, 501 Ventures.
Exclusive: AI drug discovery startup Iambic raised $100M from investors to expand its HER2 program and advance two more drugs into trials in 2026.
Exclusive: AI biotech Iambic raises $100M, expects three drugs in clinic in 2026
Iambic has raised more than $100 million in a new funding round, CEO Tom Miller exclusively told Endpoints News, and the San Diego biotech plans on using the cash to advance multiple drugs in the clin...
endpoints.news
November 10, 2025 at 5:05 PM
Exclusive: AI drug discovery startup Iambic raised $100M from investors to expand its HER2 program and advance two more drugs into trials in 2026.
Roche’s BTK inhibitor hit Phase 3 goals in two MS studies — a rare double win for a class long beset by safety issues and trial failures.
Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosis
Roche’s BTK inhibitor has cleared two registrational studies in different types of multiple sclerosis, a surprise turn for a drug class that’s seen several trial failures and safety setbacks.
endpoints.news
November 10, 2025 at 4:07 PM
Roche’s BTK inhibitor hit Phase 3 goals in two MS studies — a rare double win for a class long beset by safety issues and trial failures.
Akeso and Summit’s PD-1xVEGF bispecific ivonescimab cut the risk of death by 26% in a China lung cancer study, showing the first survival benefit using immunotherapy for this group.
Akeso, Summit’s PD-1xVEGF bispecific extends life in China lung cancer study
Researchers reported that adding Akeso and Summit Therapeutics’ ivonescimab to chemotherapy cut the risk of death by 26% in a study conducted in China for a certain form of lung cancer.
endpoints.news
November 7, 2025 at 8:26 PM
Akeso and Summit’s PD-1xVEGF bispecific ivonescimab cut the risk of death by 26% in a China lung cancer study, showing the first survival benefit using immunotherapy for this group.
Lilly hired Denali’s Carole Ho to lead neuroscience and promoted Adrienne Brown to head immunology, while expanding roles for top execs.
Lilly hires Denali executive to run neuroscience division
Eli Lilly is shaking up its neuroscience and immunology leadership, while giving two longtime executives additional responsibilities.
endpoints.news
November 7, 2025 at 7:00 PM
Lilly hired Denali’s Carole Ho to lead neuroscience and promoted Adrienne Brown to head immunology, while expanding roles for top execs.
In this week’s Peer Review: As Novo and Pfizer spar over Metsera, both make leadership moves — Novo sees key exits, while Pfizer names a new R&D chief. Read the full job update:
Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera
While Novo reveals more high-level departures, Pfizer welcomes the former CSO of Blueprint Medicines.
endpoints.news
November 7, 2025 at 4:42 PM
In this week’s Peer Review: As Novo and Pfizer spar over Metsera, both make leadership moves — Novo sees key exits, while Pfizer names a new R&D chief. Read the full job update:
A patient in Intellia’s CRISPR trial died after being hospitalized with severe liver injury.
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury
Patient in 80s dies after receiving Intellia Therapeutics' CRISPR therapy nex-z for ATTR. Death follows liver injury; exact cause unclear. CEO John Leonard announces trial pause.
endpoints.news
November 7, 2025 at 3:22 PM
A patient in Intellia’s CRISPR trial died after being hospitalized with severe liver injury.
Oura raised $900M in a round valuing the company at $11B to expand into AI, global markets, and healthcare as the smart ring maker’s medical ambitions take shape.
Oura’s healthcare ambitions take shape as the smart ring maker vaults to a $11B valuation
Oura in October raised $900 million in a Series E round that valued the company at $11 billion. As it looks to grow, healthcare is becoming an increasingly important part of Oura’s strategy.
endpoints.news
November 6, 2025 at 9:10 PM
Oura raised $900M in a round valuing the company at $11B to expand into AI, global markets, and healthcare as the smart ring maker’s medical ambitions take shape.
🚨 Trump struck major deals with Lilly and Novo to slash GLP-1 drug prices to $350 a month in exchange for Medicare coverage and tariff relief.
Trump lands sweeping cost cuts on Lilly, Novo weight loss drugs in exchange for Medicare coverage
The White House on Thursday unveiled multifaceted deals with Eli Lilly and Novo Nordisk, securing discounts for their megablockbuster GLP-1 drugs in exchange for Medicare coverage.
endpoints.news
November 6, 2025 at 5:16 PM
🚨 Trump struck major deals with Lilly and Novo to slash GLP-1 drug prices to $350 a month in exchange for Medicare coverage and tariff relief.
⚡ Breaking: Novo raises Metsera offer again
Breaking: Novo Nordisk raises Metsera bid again, hoping to top Pfizer's latest offer
Novo has once again upped its bid for Metsera, according to sources familiar with the matter, in an effort to beat out a raised Pfizer offer that was delivered late Wednesday.
endpoints.news
November 6, 2025 at 4:19 PM
⚡ Breaking: Novo raises Metsera offer again
Join us online today at 11 AM ET: Health tech, data sharing, and AI are redefining care under the Trump Administration. Hear from Hinge Health’s Daniel Perez and experts at ŌURA, Oracle, and the Digital Medicine Society. Don't miss it — register now.
ENDPOINTS Health Tech Day 2025
Health technology is in the spotlight. Despite dour fundraising trends in most areas of healthcare, the sector is seeing strong investment. RFK Jr. and the Trump administration are making big statemen...
events.endpoints.news
November 6, 2025 at 3:11 PM
Join us online today at 11 AM ET: Health tech, data sharing, and AI are redefining care under the Trump Administration. Hear from Hinge Health’s Daniel Perez and experts at ŌURA, Oracle, and the Digital Medicine Society. Don't miss it — register now.
China lifted its import ban on Illumina’s DNA sequencers after trade talks, reopening a key market even as it remains on the ‘unreliable entities’ list.
China lifts import ban on Illumina's DNA sequencers as trade tensions ease
China lifts import ban on Illumina DNA sequencers after US trade talks, though company remains on
endpoints.news
November 6, 2025 at 2:47 PM
China lifted its import ban on Illumina’s DNA sequencers after trade talks, reopening a key market even as it remains on the ‘unreliable entities’ list.
⚡ Breaking: Delaware judge refuses to block Metsera from ending Pfizer obesity deal
Breaking: Delaware judge refuses to block Metsera from ending Pfizer obesity deal
Judge denies Pfizer's restraining order against Metsera, clearing path for potential $10B Novo Nordisk deal despite FTC concerns. Pfizer's original $7.3B deal at risk.
endpoints.news
November 5, 2025 at 9:57 PM
⚡ Breaking: Delaware judge refuses to block Metsera from ending Pfizer obesity deal
Braveheart Bio raised $185M to advance its heart drug into a late-stage global trial in 2026. The biotech also named Biogen CEO Chris Viehbacher as its new chair.
Cardio biotech Braveheart gets $185M, names Biogen CEO as its chair
Braveheart Bio has collected $185 million from leading biotech investors to start registration-enabling studies for a cardiovascular drug it licensed from Hengrui, one of the biggest drug developers i...
endpoints.news
November 5, 2025 at 9:53 PM
Braveheart Bio raised $185M to advance its heart drug into a late-stage global trial in 2026. The biotech also named Biogen CEO Chris Viehbacher as its new chair.
⚡ Breaking: FTC raises doubts about Novo's bid for Metsera
Breaking: FTC raises concerns about structure of Novo Nordisk's bid for Metsera
The FTC says Novo's offer could circumvent the normal antitrust review process for deals under the Hart-Scott-Rodino Act.
endpoints.news
November 5, 2025 at 8:15 PM
⚡ Breaking: FTC raises doubts about Novo's bid for Metsera
The FDA rejected Biohaven’s ataxia drug troriluzole, citing issues with real-world data — marking the biotech’s second failed bid for approval.
FDA rejects Biohaven's ataxia drug, shutting down company's second attempt to win approval
FDA rejects Biohaven's troriluzole for spinocerebellar ataxia due to real-world evidence concerns, leading company to cut costs and pause programs. Shares fell 40%.
endpoints.news
November 5, 2025 at 6:39 PM
The FDA rejected Biohaven’s ataxia drug troriluzole, citing issues with real-world data — marking the biotech’s second failed bid for approval.
Exclusive: Backed by former Google CEO Eric Schmidt, research group FutureHouse unveiled its AI scientist Kosmos and a for-profit spinoff, Edison Scientific.
Exclusive: Research institute FutureHouse debuts AI scientist and for-profit spinoff
FutureHouse launches Kosmos widely & creates Edison Scientific spinoff to manage AI tools.
endpoints.news
November 5, 2025 at 4:39 PM
Exclusive: Backed by former Google CEO Eric Schmidt, research group FutureHouse unveiled its AI scientist Kosmos and a for-profit spinoff, Edison Scientific.
Novo Nordisk’s Q3 sales missed forecasts as rival Lilly surged, underscoring Novo’s need for a Metsera deal and possible relief from a GLP-1 pricing pact with the White House.
Novo Nordisk sales miss underlines its need for Metsera
Novo Nordisk CEO Doustdar avoids Metsera bid questions, reports weak Q3 sales of $11.5B. Company cuts pipeline assets and narrows 2025 profit guidance amid competition from Eli Lilly.
endpoints.news
November 5, 2025 at 3:15 PM
Novo Nordisk’s Q3 sales missed forecasts as rival Lilly surged, underscoring Novo’s need for a Metsera deal and possible relief from a GLP-1 pricing pact with the White House.
Jennifer Doudna’s Azalea Therapeutics launched with $82M to develop in vivo CAR-T therapies using a new CRISPR delivery system called EDVs, or Enveloped Delivery Vehicles.
Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T
Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.
endpoints.news
November 4, 2025 at 10:04 PM
Jennifer Doudna’s Azalea Therapeutics launched with $82M to develop in vivo CAR-T therapies using a new CRISPR delivery system called EDVs, or Enveloped Delivery Vehicles.
Novo Nordisk raised its Metsera bid to as much as $10B, topping Pfizer’s latest $8.1B offer as the two pharma giants battle for the obesity biotech.
Updated: Novo ups Metsera bid to as much as $10B in attempt to top Pfizer's new offer
Hours before a pivotal court hearing, Novo Nordisk has increased its offer for obesity biotech Metsera to as much as $10 billion, trying to outdo a new offer by Pfizer.
endpoints.news
November 4, 2025 at 8:15 PM
Novo Nordisk raised its Metsera bid to as much as $10B, topping Pfizer’s latest $8.1B offer as the two pharma giants battle for the obesity biotech.
Blackstone has said it will pay Merck $700M for an antibody-drug conjugate.
Blackstone to pay Merck $700M to fund development of antibody-drug conjugate
Blackstone Life Sciences provides $700M to Merck for development of sac-TMT, an antibody-drug conjugate licensed from Kelun Pharmaceutical, in exchange for royalties.
endpoints.news
November 4, 2025 at 4:47 PM
Blackstone has said it will pay Merck $700M for an antibody-drug conjugate.
⚡ Breaking: Novo and Lilly near White House deal on obesity drugs
Breaking: Lilly and Novo near White House deal on obesity drug prices
Eli Lilly and Novo Nordisk are nearing a White House deal to price weight loss drugs at $149 per month in exchange for Medicare coverage, sources say.
endpoints.news
November 4, 2025 at 3:24 PM
⚡ Breaking: Novo and Lilly near White House deal on obesity drugs
What does Big Pharma really think of the UK? @financialtimes.com global pharmaceutical editor Hannah Kuchler joins us to break down how drugmakers are operating across the pond. Live today at 11 AM ET.
endpoints.news/post-hoc-liv...
endpoints.news/post-hoc-liv...
November 4, 2025 at 2:11 PM
What does Big Pharma really think of the UK? @financialtimes.com global pharmaceutical editor Hannah Kuchler joins us to break down how drugmakers are operating across the pond. Live today at 11 AM ET.
endpoints.news/post-hoc-liv...
endpoints.news/post-hoc-liv...